Madrigal Pharmaceuticals, Inc.
MDGL· Nasdaq
Released Jul 30, 2026, before the open
10-Q filed Jul 30, 2026, 30 days after period end · 0001628280-26-050845
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $364.25M | $212.80M | $14.64M | $0.00 |
| Net Income | -$57.94M | -$42.28M | -$151.97M | -$85.80M |
| EPS Diluted |
Madrigal Pharmaceuticals, Inc. · CIK 1157601 · Engraved from SEC EDGAR
| -$1.99 |
| -$1.50 |
| -$7.10 |
| -$4.69 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.